In the Phase 3 ORIENT‐11 trial, another PD‐1 inhibitor, sintilimab, was investigated in combination with chemotherapy vs. chemotherapy alone as a first‐line treatment for Chinese patients diagnosed with locally advanced or metastatic nonsquamous NSCLC [42]. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.